Skip to main content
Assets
Nestlé logo
NESN.SIX
Nestlé
Consumer Staples · Packaged Foods & Meats

Global food and beverage company known for brands like Nescafé, KitKat, Gerber, and Purina with operations in 186 countries.

HQ: SwitzerlandListed: Switzerland

Historical AI Consensus

Audit every published iPulse AI forecast batch and immutable historical research document for Nestlé.

Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol
NESN.SIX
Batch
7
Published
September 20, 2026
AI Advisors
14

Historical AI Consensus Investment Thesis

Nestlé (NESN) Stock Forecast and AI Rating

Original pricing snapshot Deep analysis published 12 min read
Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

81 CHF

+6.3%+8.5% incl. dividends
2031

5-Year

BUY

104 CHF

+36.5%+50.7% incl. dividends

Published batch insight

Operating Cash Rebound Clashes With Heavy Balance Sheet Leverage And Currency Drag

Across submitted evaluations there is high consensus that recovering volume momentum, soft commodity deflation, and overhead restructuring will restore underlying cash conversion. Nevertheless, persistent Swiss franc currency translation headwinds, balance-sheet leverage, and retailer pushback constrain valuation multiple expansion, anchoring total shareholder returns primarily in dependable dividend yields.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist) advisor portraitUniversal Investor (Polymath) advisor portraitElon Musk (Visionary) advisor portraitMichael Burry (Vulture) advisor portraitSuperintelligence (Anthropologist) advisor portraitRay Dalio (Strategist) advisor portraitSherlock Holmes (Whistleblower) advisor portraitMachiavelli (Insider) advisor portraitJ.P. Morgan (Titan) advisor portrait

Warren Buffett (Value Purist), Universal Investor (Polymath), Elon Musk (Visionary), Michael Burry (Vulture), Superintelligence (Anthropologist), Ray Dalio (Strategist), Sherlock Holmes (Whistleblower), Machiavelli (Insider), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models
Gemini AI model logoGeminiClaude AI model logoClaudeChatGPT AI model logoChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Nestlé at the forecast anchor (2026-09-18): $15,808 in five years versus $13,892 for S&P 500 benchmark.

Five-year synthesized consensus forecast for NestléThe diagram shows the synthesized consensus value path for Nestlé, forecast milestones, and a comparison with S&P 500 benchmark. including estimated net dividends of 2.0% per year.$10,000$12,500$15,000$17,500$15,808 (+58.1%)$13,892 (+38.9%)Anchor2026-09-182027(1Y)2028(2Y)2029(3Y)2030(4Y)2031(5Y)
Nestlé · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.0% net dividend yield for Nestlé.

Figure: Five-year synthesized consensus value path for Nestlé compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each step

Frozen forecast from 18 Sept 2026. Prices in CHF; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 76.27 CHF1-year price return: +6.34%5-year price return: +36.48%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in CHF, with returns and rationale
QuarterTarget (CHF)Quarter returnTotal returnForecast rationale
Q4 202676.77+0.65%+0.65%Third-quarter volume stabilization in petcare and coffee cushions upfront restructuring charges under Navratil's overhaul. Moderating cocoa spot prices provide early gross margin support, though safe-haven Swiss franc strength limits reported equity appreciation.
Q1 202778.78+2.62%+3.29%Full-year 2026 financial reporting validates gross margin recovery and confirms initial overhead savings exceeding CHF 1.5 billion. Credible trading margin guidance and a maintained dividend reassure income investors, driving constructive defensive portfolio accumulation.
Q2 202779.76+1.25%+4.58%The routine annual dividend detachment creates a temporary mechanical price drag that is cushioned by closing the Peranel water partnership. Solid emerging market volume momentum counterbalances persistent European supermarket pushback on pricing.
Q3 202781.10+1.68%+6.34%First-half 2027 results reveal tangible operating leverage as lower soft commodity procurement costs feed into earnings. Accelerating real internal growth across North America offsets ongoing currency translation friction, supporting steady quarterly valuation progress.
Q4 202782.80+2.10%+8.57%Realized overhead reductions approach targeted run-rates, releasing working capital into the fiscal year-end. Concentrated advertising across core power brands successfully defends market share against hard discounters, solidifying operational turnaround credibility.
Q1 202884.86+2.48%+11.26%Fiscal 2027 reporting confirms trading operating margins expanding toward 16.8%, underpinned by restructuring delivery and commodity normalization. Rebounding free cash flow reassures institutional allocators, prompting modest valuation multiple re-rating across major European bourses.
Q2 202885.61+0.89%+12.25%Seasonal dividend distribution extraction is absorbed smoothly as Purina PetCare and Nespresso post resilient second-quarter volume expansion. Expanded factory automation investments begin lowering conversion costs, cushioning gross profitability against localized wage inflation.
Q3 202887.58+2.30%+14.83%First-half 2028 disclosures demonstrate sustained organic volume expansion, led by Latin American and Indian distribution gains. Softening agricultural procurement costs widen gross margins, while ongoing balance-sheet deleveraging steadily lowers recurring net financing expenses.
Q4 202889.15+1.79%+16.89%Year-end balance sheet progress brings net debt toward target ratios, clearing the path for prospective share repurchase resumptions. Strong seasonal confectionery and premium beverage shipments sustain healthy cash generation despite broader macroeconomic deceleration.
Q1 202991.06+2.14%+19.39%Full-year 2028 results validate achievement of the CHF 3.0 billion structural cost reduction milestone. Management's announcement of a disciplined share buyback program alongside dividend growth re-establishes the equity's compounding total return narrative.
Q2 202991.71+0.72%+20.25%The annual dividend deduction temporarily trims quoted prices, but steady demand for daily nutritional essentials provides reliable floor support. Clinical nutrition and specialized pet therapeutics maintain premium pricing, dampening broader European consumer spending headwinds.
Q3 202993.09+1.50%+22.05%First-half 2029 performance highlights durable 3.5% organic revenue growth, anchored by high-margin healthcare and premium coffee innovations. Automated supply chain hubs reduce operating expenses, allowing operating leverage to flow directly into expanded per-share earnings.
Q4 202994.76+1.79%+24.24%Disciplined working capital optimization and robust seasonal cash collection deliver strong year-end free cash conversion. Active share repurchases consistently reduce diluted share counts, insulating equity valuation against late-cycle global market volatility.
Q1 203096.56+1.90%+26.60%Fiscal 2029 financial statements confirm operating profit margins stabilizing firmly above 17.0%. Long-term quality investors reward predictable cash conversion and balance sheet rehabilitation, driving methodical multiple re-rating toward historical consumer defensive medians.
Q2 203097.08+0.54%+27.28%Post-dividend price recovery proves orderly as emerging market urbanization fuels double-digit volume expansion in fortified nutrition. Disciplined SKU management keeps inventory turns lean, minimizing warehouse carrying costs and defending consolidated operating returns.
Q3 203098.76+1.73%+29.48%Mid-year 2030 results demonstrate sustained volume growth across diverse geographic zones, confirming the durability of the four-pillar portfolio. Prudent leverage metrics comfortably below 2.0x EBITDA preserve high investment-grade credit ratings and minimize refinancing friction.
Q4 2030100.19+1.45%+31.36%Defensive institutional positioning favors dependable cash flow generators as global economic growth moderates. Specialized medical nutrition platforms continue gaining commercial traction, providing structural margin insulation against residual packaging and transport cost pressures.
Q1 2031101.95+1.76%+33.67%Audited full-year 2030 results show normalized operating margins holding at 17.2% with free cash flow surpassing CHF 12 billion. Another consecutive dividend increase reinforces elite dividend aristocrat credentials, sustaining steady institutional capital accumulation.
Q2 2031102.55+0.59%+34.46%Routine annual dividend distribution extraction is easily absorbed as core petcare and coffee categories exhibit near-zero price elasticity. Stable agricultural commodity input costs preserve healthy unit economics, ensuring predictable quarterly operational cash conversion.
Q3 2031104.09+1.50%+36.48%The five-year strategic overhaul concludes with restored volume growth, structurally higher operating profitability, and a de-risked balance sheet. Terminal equity valuation reflects an enduring defensive consumer compounder driven by disciplined capital allocation and compounding dividends.

The enterprise is executing a classic operational self-help turnaround as real internal growth inflects positively and cumulative restructuring efficiencies expand trading operating margins. Soft agricultural commodity deflation in green coffee and cocoa lags spot markets by six to nine months, creating mechanical gross margin expansion through upcoming reporting cycles. However, valuation sensitivity is bounded by a restrictive sovereign discount rate and elevated balance-sheet leverage, where net debt exceeds CHF 56 billion and progressive dividends absorb nearly 85% of normalized free cash flow. Persistent safe-haven Swiss franc translation friction further dampens reported top-line progression and limits unencumbered multiple re-rating.

Key insights

  • Accounting net profit distortion obscures underlying cash generation, as front-loaded restructuring charges and held-for-sale impairments mask resilient operating free cash flows.
  • Portfolio triage through water carve-outs trades consolidated sales volume for balance-sheet liquidity, reducing recurring regulatory liabilities without creating dilutive equity overhang.
  • Reallocating efficiency savings directly into brand marketing defends volume against private labels but structurally limits the net margin conversion to equity.

Deep Dive

Market consensus treats the company as an exhausted defensive bond proxy impaired by sluggish volume growth, elevated soft commodity costs, and executive churn. Investors anchor heavily on depressed headline net profits and GLP-1 demand destruction fears, assuming brand pricing power has permanently broken against retail private labels. Sell-side price targets reflect an unenthusiastic hold stance, expecting dividends to serve as the sole investment rationale.